Thymomas are rare tumours which generally account for only 0.2 - 1.5% of mediastinal tumours in adults. Around 40% of patients present with systemic symptoms such as motor weakness due to myasthenia gravis (MG), pure red cell aplasia, and hypogammaglobulinemia. Based on recent guidelines, management of advanced thymoma uses a multimodal approach, which is thymectomy followed by radiotherapy, but not all health care centers have radiotherapy facilities. A 52-year-old woman presented with nasal voice and had difficulty swallowing food. Patient was diagnosed with myasthenia gravis (MG). CT scan with contrast of the thorax showed a heterogenous solid mass in anterior mediastinum. Histopathological examination showed thymoma type B2. Thymectomy followed by seven cycles of platinum-based chemotherapy were done on the patient. Evaluation afterward showed complete remission of thymoma. The patient's motor weakness improved after the chemotherapy. Post-chemotherapy period was uneventful at six months on follow-up visit. The dosage of acetylcholinesterase inhibitor drug is reduced periodically due to improvement in motor weakness. The case emphasizes how to manage an advanced thymoma with MG with limited therapeutic options, and the importance of multidisciplinary management involving oncologists, surgeons, and neurologists.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11779666 | PMC |
http://dx.doi.org/10.47895/amp.vi0.8074 | DOI Listing |
World J Cardiol
February 2025
Department of Oncology, Chongqing Medical University Affiliated Third Hospital, Chongqing 400020, China.
Background: Cardiac metastatic tumors (CMTs) are rare yet pose significant medical concerns. Clinical studies on CMT are limited, particularly those involving multicenter data analysis.
Aim: To systematically analyze the etiology, sources, classification, treatment, and prognosis of CMT.
Cancer Imaging
March 2025
Thoracic Surgical Department, The Affiliated Huaian No. 1 People's Hospital of Nanjing Medical University, Huai'an, PR China.
Background: Apart from rare cases such as lymphomas, germ cell tumors, neuroendocrine neoplasms, and thymic hyperplasia, thymic mass lesions (TMLs) are typically categorized into cysts, and thymomas. However, the classification results cannot be determined in advance and can only be confirmed through postoperative pathology. Therefore, the objective of this study is to rely on clinical parameters and radiomic features extracted from chest computed tomography (CT) scans to facilitate the preoperative classification of TMLs.
View Article and Find Full Text PDFLancet Oncol
March 2025
Department of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Background: Despite the poor prognosis of advanced or recurrent thymic carcinoma, the rarity of thymic carcinoma has delayed the development and introduction of novel pharmacotherapy options. Carboplatin plus paclitaxel remains a standard treatment for chemotherapy-naive advanced or recurrent thymic carcinoma. We evaluated the activity and safety of atezolizumab combined with chemotherapy.
View Article and Find Full Text PDFJ Thorac Dis
January 2025
Department of Thoracic Surgery, Guy's Hospital, Guy's and St. Thomas' Hospital NHS Trust, London, UK.
Background: Thymic epithelial tumors (TETs) represent the predominant primary malignancy of the anterior mediastinum, often necessitating complex surgical interventions due to their invasive nature. The prognosis of advanced TET relies significantly on achieving complete resection with microscopically clear margins (R0). This frequently entails resection and reconstruction of major vascular structures like the superior vena cava (SVC) and brachiocephalic veins, and in some cases, extra pleural pneumonectomy (EPP).
View Article and Find Full Text PDFActa Med Philipp
January 2025
Department of Internal Medicine, Faculty of Medicine, University of Udayana / Prof. Dr. I.G.N.G. Ngoerah General Hospital, Denpasar, Bali, Indonesia.
Thymomas are rare tumours which generally account for only 0.2 - 1.5% of mediastinal tumours in adults.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!